2OZR

MMP13 Catalytic Domain Complexed with 4-{[1-methyl-2,4-dioxo-6-(3-phenylprop-1-yn-1-yl)-1,4-dihydroquinazolin-3(2H)-yl]methyl}benzoic acid


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 0.340 
  • R-Value Work: 0.248 
  • R-Value Observed: 0.253 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.5 of the entry. See complete history


Literature

Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.

Johnson, A.R.Pavlovsky, A.G.Ortwine, D.F.Prior, F.Man, C.F.Bornemeier, D.A.Banotai, C.A.Mueller, W.T.McConnell, P.Yan, C.Baragi, V.Lesch, C.Roark, W.H.Wilson, M.Datta, K.Guzman, R.Han, H.K.Dyer, R.D.

(2007) J Biol Chem 282: 27781-27791

  • DOI: https://doi.org/10.1074/jbc.M703286200
  • Primary Citation of Related Structures:  
    2OW9, 2OZR

  • PubMed Abstract: 

    Matrix metalloproteinase-13 (MMP13) is a Zn(2+)-dependent protease that catalyzes the cleavage of type II collagen, the main structural protein in articular cartilage. Excess MMP13 activity causes cartilage degradation in osteoarthritis, making this protease an attractive therapeutic target. However, clinically tested MMP inhibitors have been associated with a painful, joint-stiffening musculoskeletal side effect that may be due to their lack of selectivity. In our efforts to develop a disease-modifying osteoarthritis drug, we have discovered MMP13 inhibitors that differ greatly from previous MMP inhibitors; they do not bind to the catalytic zinc ion, they are noncompetitive with respect to substrate binding, and they show extreme selectivity for inhibiting MMP13. By structure-based drug design, we generated an orally active MMP13 inhibitor that effectively reduces cartilage damage in vivo and does not induce joint fibroplasias in a rat model of musculoskeletal syndrome side effects. Thus, highly selective inhibition of MMP13 in patients may overcome the major safety and efficacy challenges that have limited previously tested non-selective MMP inhibitors. MMP13 inhibitors such as the ones described here will help further define the role of this protease in arthritis and other diseases and may soon lead to drugs that safely halt cartilage damage in patients.


  • Organizational Affiliation

    Department of Inflammation Molecular Sciences, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA. adam.johnson@pfizer.com


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Collagenase 3
A, B, C, D, E
A, B, C, D, E, F, G, H
170Homo sapiensMutation(s): 0 
Gene Names: MMP13
EC: 3.4.24
UniProt & NIH Common Fund Data Resources
Find proteins for P45452 (Homo sapiens)
Explore P45452 
Go to UniProtKB:  P45452
PHAROS:  P45452
GTEx:  ENSG00000137745 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP45452
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 4 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
GG1
Query on GG1

Download Ideal Coordinates CCD File 
BB [auth G]
GA [auth D]
HB [auth H]
N [auth A]
NA [auth E]
BB [auth G],
GA [auth D],
HB [auth H],
N [auth A],
NA [auth E],
T [auth B],
UA [auth F],
Z [auth C]
4-{[1-METHYL-2,4-DIOXO-6-(3-PHENYLPROP-1-YN-1-YL)-1,4-DIHYDROQUINAZOLIN-3(2H)-YL]METHYL}BENZOIC ACID
C26 H20 N2 O4
FLTYDFYSVZBKOB-UHFFFAOYSA-N
HAE
Query on HAE

Download Ideal Coordinates CCD File 
AA [auth C],
HA [auth D],
OA [auth E],
VA [auth F]
ACETOHYDROXAMIC ACID
C2 H5 N O2
RRUDCFGSUDOHDG-UHFFFAOYSA-N
ZN
Query on ZN

Download Ideal Coordinates CCD File 
BA [auth D]
CA [auth D]
CB [auth H]
DB [auth H]
I [auth A]
BA [auth D],
CA [auth D],
CB [auth H],
DB [auth H],
I [auth A],
IA [auth E],
J [auth A],
JA [auth E],
O [auth B],
P [auth B],
PA [auth F],
QA [auth F],
U [auth C],
V [auth C],
WA [auth G],
XA [auth G]
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
CA
Query on CA

Download Ideal Coordinates CCD File 
AB [auth G]
DA [auth D]
EA [auth D]
EB [auth H]
FA [auth D]
AB [auth G],
DA [auth D],
EA [auth D],
EB [auth H],
FA [auth D],
FB [auth H],
GB [auth H],
K [auth A],
KA [auth E],
L [auth A],
LA [auth E],
M [auth A],
MA [auth E],
Q [auth B],
R [auth B],
RA [auth F],
S [auth B],
SA [auth F],
TA [auth F],
W [auth C],
X [auth C],
Y [auth C],
YA [auth G],
ZA [auth G]
CALCIUM ION
Ca
BHPQYMZQTOCNFJ-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
GG1 BindingDB:  2OZR IC50: min: 0.67, max: 14 (nM) from 2 assay(s)
PDBBind:  2OZR IC50: 0.67 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 0.340 
  • R-Value Work: 0.248 
  • R-Value Observed: 0.253 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 161.836α = 90
b = 71.974β = 124.59
c = 138.13γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling
REFMACrefinement
PDB_EXTRACTdata extraction
ADSCdata collection
HKL-2000data reduction
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2007-07-24
    Type: Initial release
  • Version 1.1: 2007-10-03
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Advisory, Derived calculations, Version format compliance
  • Version 1.3: 2017-10-18
    Changes: Refinement description
  • Version 1.4: 2023-08-30
    Changes: Data collection, Database references, Derived calculations, Refinement description
  • Version 1.5: 2024-03-13
    Changes: Source and taxonomy, Structure summary